<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320030</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2019-04</org_study_id>
    <nct_id>NCT04320030</nct_id>
  </id_info>
  <brief_title>[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers</brief_title>
  <acronym>EITHICS</acronym>
  <official_title>Pilot Feasibility Study: Inflammation and Presence of M2 Macrophages Explorations With[18F]-DPA-714 PET/CT in Triple Negative Breast Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SIRIC ILIAD : regional consortium led by the health cooperation consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study is assessing the correlation between M1/M2 macrophage polarization
      determined by tumor immunohistochemistry analysis and [18F]DPA-714 PET/CT binding
      (qualitative and texture analysis) in patients with operable triple negative breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the correlation of inflammation assessed by M1/M2
      macrophage polarization determined by tumor immunohistochemistry analysis and [18F] DPA-714
      PET imaging by using qualitative and image texture analysis in patients with triple negative
      breast cancer.

      Patients receive pre-therapeutic diffusion-weighted breast MRI (Magnetic resonance imaging)
      and 18FDG (fluorodeoxyglucose) PET/CT (Positron Emission Tomography/Computerized Tomography)
      scan within 30 days before enrollment.

      [18F] DPA-714 PET/CT scan is performed before surgery. About 3 MBq/Kg of [18F] DPA-714 are
      injected intravenously, two acquisition sequences are performed following injection and 60
      minutes after injection in order to evaluate early and late tumor uptake of [18F] DPA-714.

      Surgery is scheduled after [18F] DPA-714 PET/CT scan. Tissue samples from breast surgery are
      used to assess M1 and M2 macrophages expression and to perform tumor molecular subtyping by
      Immunohistochemical analysis. Tumor Autoradiography with the TSPO (18 kDa Translocator
      Protein) ligand [18F]DPA-714 will be also assessed on tumor tissue.

      A blood sample is performed before [18F] DPA-714 PET/CT scan in order to assess the
      genotyping of TSPO (18 kDa Translocator Protein) gene.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicentric, open prospective study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between M1/M2 macrophage polarization and [18F]DPA-714 PET/CT binding</measure>
    <time_frame>18 months</time_frame>
    <description>M1/M2 macrophage polarization will be assessed by tumor immunohistochemistry analysis, [18F]DPA-714 PET/CT binding will be assessed by qualitative and images texture analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between TSPO genotyping (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder) and [18F]DPA-714 PET/CT binding</measure>
    <time_frame>18 months</time_frame>
    <description>A blood sample is performed before [18F] DPA-714 PET/CT scan in order to assess the genotyping of TSPO gene at the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the value of early and late [18F]-DPA-714 PET/CT acquisitions</measure>
    <time_frame>18 months</time_frame>
    <description>Early and Late tumor uptake of [18F]-DPA-714 will be assessed by qualitative and quantitative parameters measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the performance of the three types of imaging used in this study: [18F]-DPA-714 PET/CT (early and late), 18FDG PET/CT and diffusion-weighted breast MRI in the characterization of triple negative breast cancer</measure>
    <time_frame>18 months</time_frame>
    <description>This evaluation will be done by image texture analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perform tumor molecular subtyping</measure>
    <time_frame>18 months</time_frame>
    <description>This tumor molecular subtyping will be performed on breast surgery tissue samples by immuno-histochemical analysis using a panel of antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[18F]-DPA-714 toxicity</measure>
    <time_frame>18 months</time_frame>
    <description>[18F]-DPA-714 toxicity will be assessed by vital signs monitoring within 2 hours after [18F]-DPA-714 injection. Body Temperature, Pulse Rate and Blood Pressure will be mesured within two hours after [18F]-DPA-714 injection. All adverse events due to [18F]-DPA-714 will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>[18F]-DPA-714</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pretherapeutic [18F]-DPA-714 PET/CT scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]-DPA-714 PET/CT scan</intervention_name>
    <description>Pretherapeutic [18F]-DPA-714 PET/CT scan</description>
    <arm_group_label>[18F]-DPA-714</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 Years and older

          -  Triple negative primary breast cancer based on immunohistochemical results as follows:

               -  Estrogen receptor &lt; 10%

               -  And Progesterone receptors &lt; 10%

               -  And HER2 (Human Epidermal Growth Factor Receptor-2) not amplified or not
                  overexpressed

          -  Patient with a primary tumor eligible for primary surgery

          -  Performance Status equal to 0 or 1

          -  Fertile patients must use effective contraception

          -  Patient must be affiliated to a Social Health Insurance

          -  Written informed consent

        Exclusion Criteria:

          -  Patient with No triple negative breast cancer

          -  Patient with inflammatory breast cancer

          -  Patient with metastatic breast cancer

          -  Patient receiving cancer treatments such as chemotherapy, immunotherapy, biologic
             response modifiers, hormonal therapy, and radiotherapy BEFORE the biopsy and PET scans
             are performed

          -  Treated diabetes with fasting blood glucose &gt; 10 mmol/L

          -  Patient who received antibiotics and/or steroidal and/or non-steroidal
             anti-inflammatory drugs within 30 days PRIOR to [18F]-DPA-714 PET scan

          -  Contraindication to MRI (implants or metallic prosthesis, severe claustrophobia,
             pacemaker ...)

          -  Patient deprived of liberty, under a measure of safeguard of justice, under
             guardianship or under the authority of a guardian

          -  Pregnant or nursing patient

          -  Agitation; impossibility of lying motionless for at least 1 hour, or known
             claustrophobia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline ROUSSEAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline ROUSSEAU, MD, PhD</last_name>
    <phone>+33240679931</phone>
    <email>caroline.rousseau@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia FLEURY, PhD</last_name>
    <phone>+33240679826</phone>
    <email>nadia.fleury@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cacerologie de l'ouest - site Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>GIRAULT Sylvie, MD</last_name>
      <phone>+33241352700</phone>
      <email>sylvie.girault@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>MONTRAVERS Françoise, MD, PhD</last_name>
      <phone>+33156017326</phone>
      <email>francoise.montravers@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline ROUSSEAU, MD, PhD</last_name>
      <phone>+33240679931</phone>
      <email>caroline.rousseau@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>OULDAMER Lobna, MD, PhD</last_name>
      <phone>+33247474741</phone>
      <email>lobna.ouldamer@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>[18F]-DPA-714</keyword>
  <keyword>Positron Emission Tomography/Computerized Tomography (PET/CT) scan</keyword>
  <keyword>18 kDa Translocator Protein (TSPO)</keyword>
  <keyword>Macrophages M1 and M2 detection</keyword>
  <keyword>Immunohistochemical analysis</keyword>
  <keyword>Diffusion-weighted breast Magnetic resonance imaging (MRI)</keyword>
  <keyword>Tumor Autoradiography</keyword>
  <keyword>Tumor molecular subtyping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

